• Purity

  >90%, by SDS-PAGE under reducing conditions and visualized by silver stain

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by the ability of the immobilized protein to support the adhesion of BUD‑8 human fibroblast cells. When 3 x 10    ⁴ cells are added to Recombinant Mouse Desmoglein‑2 Fc Chimera coated plates (10 μg/mL, 100 μL/well), approximately 30%‑60% will adhere after 1 hour at 37 °C.    
     Optimal dilutions should be determinded by each laboratory for each application.  

• Source

  Mouse myeloma cell line, NS0-derived

  Mouse Desmoglein-2 (Leu29-Ala618) Accession # O55111	IEGRMDP	Mouse IgG2A (Gln98-Lys330)
  N-terminus		C-terminus

• Accession #

• N-terminal Sequence    
  Analysis

  Leu29 & Ala55

• Structure / Form

  Disulfide-linked homodimer

• Predicted Molecular Mass

  92.9 kDa (monomer)

• SDS-PAGE

  100-120 kDa, reducing conditions

Background: Desmoglein-2

Desmoglein-2 (DSG2) is a 160 kDa transmembrane glycoprotein in the cadherin family of calcium dependent adhesion molecules. It is a major protein component of desmosomal contacts between epithelial cells (1, 2). Mature mouse Desmoglein‑2 consists of a 564 amino acid (aa) extracellular domain (ECD) with four cadherin domains, a 21 aa transmembrane segment, and a 483 aa cytoplasmic domain with six desmoglein repeats (3, 4). Within the ECD, mouse Desmoglein‑2 shares 81% and 93% aa sequence identity with human and rat Desmoglein‑2, respectively. A 60 kDa ECD fragment can be proteolytically shed, and this is enhanced by EGF R activation (5‑7). The cytoplasmic domain is cleaved during apoptosis, leaving the transmembrane segment and ECD as a cell‑associated fragment (8). Desmoglein‑2 is widely expressed in epithelia and is required for maintenance of the epithelial barrier (1, 2, 9). It can be either up- or down‑regulated in a variety of carcinomas during tumor progression (10). Desmoglein‑2 also functions as a cell adhesion receptor for several adenovirus serotypes (11). This binding disrupts intercellular junctions between epithelial cells and promotes epithelial‑mesenchymal transition (EMT) (11). Mutations in Desmoglein‑2 cause cardiac dysfunction typical of arrythmogenic right ventricular cardiomyopathy (ARVC) (12).

• References:

1. Brooke, M.A. et al. (2012) J. Pathol. 226:158.

2. Thomason, H.A. et al. (2010) Biochem. J. 429:419.

3. Mahoney, M.G. et al. (2002) Exp. Dermatol. 11:115.

4. Whittock, N.V. (2003) J. Invest. Dermatol. 120:970.

5. Bech-Serra, J.J. et al. (2006) Mol. Cell. Biol. 26:5086.

6. Klessner, J.L. et al. (2009) Mol. Biol. Cell 20:328.

7. Ramani, V.C. et al. (2008) BMC Cancer 8:373.

8. Nava, P. et al. (2007) Mol. Biol. Cell 18:4565.

9. Schlegel, N. et al. (2010) Am. J. Physiol. Gastrointest. Liver Physiol. 298:G774.

10. Dusek, R.L. and L.D. Attardi (2011) Nat. Rev. Cancer 11:317.

11. Wang, H. et al. (2011) Nat. Med. 17:96.

12. Pilichou, K. et al. (2009) J. Exp. Med. 206:1787.

• Entrez Gene IDs:

  1829 (Human); 13511 (Mouse)

• Alternate Names:

  ARVC10; ARVD10; Cadherin family member 5; CDHF5; CDHF5MGC117034; CMD1BB; desmoglein 2; Desmoglein2; Desmoglein-2; DSG2; HDGC; MGC117036; MGC117037